

USSN: 09/205,251
Atty Dkt: DURE-021
PATENT

RECEIVED
CENTRAL FAX CENTER

APR 04 2007

COMPLETE LISTING OF CLAIMS

1 - 25. (cancelled)

26. (amended) The method of claim + 71 wherein said drug delivery unit has a volume of between 0.1 mm³ and 250 mm³.

27. (cancelled)

28. (amended) The method of claim + 71 wherein said carrier material is capable of delivering the therapeutic agent to the inner ear in nanogram to microgram quantities.

29. (amended) The method of claim + 71 wherein said therapeutic agent is present in a quantity of between about 10 wt% and 40 wt% of the total weight of the drug delivery unit.

30 - 53. (cancelled)

54. (amended) The method of claim + 71 wherein said carrier material comprises a polyanhydride material.

55. (amended) The method of claim + 71 wherein said carrier material comprises a polyorthoester material.

56. (amended) The method of claim + 71 wherein said carrier material comprises hydroxypropylmethyl cellulose.

57. (amended) The method of claim + 71 wherein said carrier material comprises hydroxyethyl cellulose.

USSN: 09/205,251
Atty Dkt: DURE-021
PATENT

58. (amended) The method of claim + 71 wherein said carrier material comprises hydrophilic microspheres.

59. (amended) The method of claim + 71 wherein said carrier material comprises a bioadhesive material.

60. (amended) The method of claim + 71 wherein said drug delivery unit is a multiphased composite drug delivery unit.

61 - 65. (cancelled)

66. (amended) The method of claim + 71 wherein said release of said therapeutic agent is achieved by osmosis, diffusion, active/passive transport, or a combination thereof.

67. (amended) The method of claim + 71, wherein the carrier material is biodegradable.

68. (amended) The method of claim + 71, wherein the carrier material is synthetic.

69. (cancelled)

70. (amended) The method of claim + 71, wherein release of the therapeutic agent from the drug delivery unit is without inadvertent delivery to other tissue regions outside the round window niche.

71. (previously added) A method for delivering a therapeutic agent into the inner ear of a living subject, said method comprising:

USSN: 09/205,251
Atty Dkt: DURE-021
PATENT

providing a drug delivery unit comprising a carrier material and a therapeutic agent combined therewith, wherein said carrier material provides for controlled release of the therapeutic agent from said drug delivery unit over time, and further wherein said drug delivery unit is configured as a pellet, disk, tablet, plate, sphere, cube, cylindrical unit, strand, ~~or plug, paste, or amorphous mass~~; and

inserting said drug delivery unit directly into the round window niche of the subject such that said unit is positioned either partially or completely within the round window niche, wherein the therapeutic agent is released from the drug delivery unit, contacts the round window membrane and passes into the inner ear.

72. (previously added) The method of claim 71 wherein said therapeutic agent is released over a period of 24 hours.

73. (previously added) The method of claim 71 wherein said therapeutic agent is released over a period of hours.

74. (previously added) The method of claim 71 wherein said therapeutic agent is released over a period of months.

75. (previously added) The method of claim 71 wherein said carrier material comprises a polymer.

76. (previously added) The method of claim 71, wherein the carrier material is biodegradable.

77. (previously added) The method of claim 71, wherein the carrier material is synthetic.

USSN: 09/205,251
Atty Dkt: DURE-021
PATENT

78. **(previously added)** The method of claim 71, wherein release of the therapeutic agent is achieved by osmosis, diffusion, active/passive transport, or a combination thereof.

79. **(cancelled)**

80. **(previously added)** The method of claim 71 wherein said therapeutic agent is selected from the group consisting of urea, mannitol, sorbitol, glycerol, lidocaine, xylocaine, epinephrine, immunoglobulins, sodium chloride, steroids, heparin, hyaluronidase, aminoglycoside antibiotics, antioxidants, neurotrophins, nerve growth factors, various therapeutic peptides, and polysaccharides.

81. **(previously added)** The method of claim 80, wherein the therapeutic agent is an aminoglycoside antibiotic.

82. **(previously added)** The method of claim 81, wherein the aminoglycoside antibiotic is gentamycin.